The role of the methoxy group in approved drugs

被引:12
作者
Chiodi, Debora [1 ]
Ishihara, Yoshihiro [2 ,3 ]
机构
[1] Takeda Pharmaceut, Dept Chem, 9625 Towne Ctr Dr, San Diego, CA 92121 USA
[2] Vivid Therapeut, Dept Chem, 5820 Nancy Ridge Dr, San Diego, CA 92121 USA
[3] Genesis Therapeut, 11568 Sorrento Valley Rd,Suite 8, San Diego, CA 92121 USA
关键词
GROWTH-FACTOR RECEPTOR; CALCIUM-CHANNEL BLOCKERS; NS3 PROTEASE INHIBITOR; PROTON PUMP INHIBITORS; TYROSINE KINASE; PHARMACOKINETIC PROPERTIES; HYDROGEN-BOND; PHARMACOLOGICAL CHARACTERIZATION; MEDICINAL CHEMISTRY; THERAPEUTIC-USE;
D O I
10.1016/j.ejmech.2024.116364
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The methoxy substituent is prevalent in natural products and, consequently, is present in many natural product -derived drugs. It has also been installed in modern drug molecules with no remnant of natural product features because medicinal chemists have been taking advantage of the benefits that this small functional group can bestow on ligand-target binding, physicochemical properties, and ADME parameters. Herein, over 230 methoxy-containing small -molecule drugs, as well as several fluoromethoxy-containing drugs, are presented from the vantage point of the methoxy group. Biochemical mechanisms of action, medicinal chemistry SAR studies, and numerous X-ray cocrystal structures are analyzed to identify the precise role of the methoxy group for many of the drugs and drug classes. Although the methoxy substituent can be considered as the hybridization of a hydroxy and a methyl group, the combination of these functionalities often results in unique effects that can amount to more than the sum of the individual parts.
引用
收藏
页数:94
相关论文
共 50 条
  • [1] A Structural Atlas of Kinases Inhibited by Clinically Approved Drugs
    Wang, Qi
    Zorn, Julie A.
    Kuriyan, John
    PROTEIN KINASE INHIBITORS IN RESEARCH AND MEDICINE, 2014, 548 : 23 - 67
  • [2] Fluorine-containing drugs approved by the FDA in 2021
    He, Jingrui
    Li, Ziyi
    Dhawan, Gagan
    Zhang, Wei
    Sorochinsky, Alexander E.
    Butler, Greg
    Soloshonok, Vadim A.
    Han, Jianlin
    CHINESE CHEMICAL LETTERS, 2023, 34 (01)
  • [3] FDA approved fluorine-containing drugs in 2023
    Wang, Qian
    Bian, Yeping
    Dhawan, Gagan
    Zhang, Wei
    Makarem, Ata
    Sorochinsky, Alexander E.
    Soloshonok, Vadim A.
    Han, Jianlin
    CHINESE CHEMICAL LETTERS, 2024, 35 (11)
  • [4] A Survey of the Structures of US FDA Approved Combination Drugs
    Das, Pradipta
    Delost, Michael D.
    Qureshi, Munaum H.
    Smith, David T.
    Njardarson, Jon T.
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (09) : 4265 - 4311
  • [5] Fluorine-containing drugs approved by the FDA in 2019
    Mei, Haibo
    Remete, Attila Mario
    Zou, Yupiao
    Moriwaki, Hiroki
    Fustero, Santos
    Kiss, Lorand
    Soloshonok, Vadim A.
    Han, Jianlin
    CHINESE CHEMICAL LETTERS, 2020, 31 (09) : 2401 - 2413
  • [6] Insights into Newly Approved Drugs from a Medicinal Chemistry Perspective
    Lima, Elys Juliane Cardoso
    Gomes, Renan Augusto
    Fornari, Evelin
    Emery, Flavio da Silva
    Trossini, Gustavo Henrique Goulart
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2021, 21 (16) : 2227 - 2248
  • [7] PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs
    Turecek, Peter L.
    Bossard, Mary J.
    Schoetens, Freddy
    Ivens, Inge A.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 105 (02) : 460 - 475
  • [8] Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016-2022)
    Shabir, Ghulam
    Saeed, Aamer
    Zahid, Wajeeha
    Naseer, Fatima
    Riaz, Zainab
    Khalil, Nafeesa
    Muneeba
    Albericio, Fernando
    PHARMACEUTICALS, 2023, 16 (08)
  • [9] In silico repurposing of FDA-approved drugs as multi-target inhibitors of glioblastoma
    Salaam, Ridwan Abiodun
    Afolayan, Funmilayo I. D.
    Olaniyi, Damilare Adebayo
    Oladokun, Sayo Ebenezer
    Ebuh, Rachael Pius
    Oyetunji, Ridwan Abiola
    SCIENTIFIC AFRICAN, 2025, 27
  • [10] Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Mao, Fei
    Ni, Wei
    Xu, Xiang
    Wang, Hui
    Wang, Jing
    Ji, Min
    Li, Jian
    MOLECULES, 2016, 21 (01):